ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $12,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $348 | $332 | $282 | $298 |
| Gross Profit | $11,652 | -$332 | -$282 | -$298 |
| % Margin | 97.1% | – | – | – |
| R&D Expenses | $42,495 | $38,000 | $22,021 | $9,314 |
| G&A Expenses | $13,240 | $9,882 | $11,825 | $7,169 |
| SG&A Expenses | $12,892 | $9,882 | $11,825 | $7,169 |
| Sales & Mktg Exp. | -$348 | $0 | $0 | $0 |
| Other Operating Expenses | -$11 | $357 | $0 | $759 |
| Operating Expenses | $55,387 | $47,882 | $33,846 | $16,483 |
| Operating Income | -$43,736 | -$47,882 | -$33,846 | -$16,483 |
| % Margin | -364.5% | – | – | – |
| Other Income/Exp. Net | -$351 | -$2,965 | $2,256 | -$488 |
| Pre-Tax Income | -$44,087 | -$51,283 | -$31,591 | -$16,971 |
| Tax Expense | $133 | $99 | $3,119 | $935 |
| Net Income | -$44,220 | -$51,382 | -$34,709 | -$17,906 |
| % Margin | -368.5% | – | – | – |
| EPS | -10.76 | -14.72 | -10.64 | -9.32 |
| % Growth | 26.9% | -38.3% | -14.2% | – |
| EPS Diluted | -10.76 | -14.72 | -10.64 | -9.32 |
| Weighted Avg Shares Out | 4,112 | 3,487 | 3,257 | 1,922 |
| Weighted Avg Shares Out Dil | 4,112 | 3,487 | 3,257 | 1,922 |
| Supplemental Information | – | – | – | – |
| Interest Income | $405 | $354 | $0 | $1 |
| Interest Expense | $4,327 | $3,676 | $1,861 | $1,247 |
| Depreciation & Amortization | $348 | $332 | $282 | $298 |
| EBITDA | -$39,403 | -$47,276 | -$29,447 | -$15,426 |
| % Margin | -328.4% | – | – | – |